Elaine Ku1,2, Charles E McCulloch3, Kirsten L Johansen4,3. 1. Division of Nephrology, Department of Medicine, University of California, San Francisco, California, USA, elaine.ku@ucsf.edu. 2. Division of Pediatric Nephrology, Department of Pediatrics, University of California, San Francisco, California, USA, elaine.ku@ucsf.edu. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA. 4. Division of Nephrology, Department of Medicine, University of California, San Francisco, California, USA.
Abstract
BACKGROUND: Studies of the timing of end-stage renal disease (ESRD) have primarily defined "early" versus "late" initiation of dialysis using estimated glomerular filtration rate (eGFR)-based criteria. Our objective was to determine the theoretical time that could be spent in chronic kidney disease (CKD) stage 5 prior to reaching a conservative eGFR threshold of 5 mL/min/1.73 m2 compared to the actual time spent in CKD stage 5 by risk factors of interest. METHODS: Eight-hundred and seventy Chronic Renal Insufficiency Cohort participants with CKD stage 5 who started renal replacement therapy (RRT) were included for retrospective study. We used mixed models to estimate the person-specific trajectory of renal function. We then used these individual trajectories to estimate the amount of time that would be spent in CKD stage 5 (between eGFR of 15 and 5 mL/min/1.73 m2) and compared this estimate to the actual time spent in CKD stage 5 prior to ESRD (between eGFR of 15 mL/min/1.73 m2 and ESRD). RESULTS: We found the median observed time between eGFR of 15 mL/min/1.73 m2 to RRT was 9.6 months, but the median predicted time between eGFR of 15 mL/min/1.73 m2 to eGFR of 5 mL/min/1.73 m2 was 17.7 months. Some of the largest differences between the predicted and actual amount of time spent in CKD stage 5 were noted among those with systolic blood pressure <140 mm Hg (9.7 months longer predicted compared to actual), proteinuria <1 g/g (9.1 months), and serum albumin ≥3.5 g/dL (9.0 months). CONCLUSION: We found marked differences between the actual and predicted time spent in CKD stage 5 based on risk factors of interest. We believe that placing timing of dialysis initiation in the perspective of time is novel and may identify subgroups of patients who may derive particular benefit from a more concerted effort to delay RRT.
BACKGROUND: Studies of the timing of end-stage renal disease (ESRD) have primarily defined "early" versus "late" initiation of dialysis using estimated glomerular filtration rate (eGFR)-based criteria. Our objective was to determine the theoretical time that could be spent in chronic kidney disease (CKD) stage 5 prior to reaching a conservative eGFR threshold of 5 mL/min/1.73 m2 compared to the actual time spent in CKD stage 5 by risk factors of interest. METHODS: Eight-hundred and seventy Chronic Renal Insufficiency Cohortparticipants with CKD stage 5 who started renal replacement therapy (RRT) were included for retrospective study. We used mixed models to estimate the person-specific trajectory of renal function. We then used these individual trajectories to estimate the amount of time that would be spent in CKD stage 5 (between eGFR of 15 and 5 mL/min/1.73 m2) and compared this estimate to the actual time spent in CKD stage 5 prior to ESRD (between eGFR of 15 mL/min/1.73 m2 and ESRD). RESULTS: We found the median observed time between eGFR of 15 mL/min/1.73 m2 to RRT was 9.6 months, but the median predicted time between eGFR of 15 mL/min/1.73 m2 to eGFR of 5 mL/min/1.73 m2 was 17.7 months. Some of the largest differences between the predicted and actual amount of time spent in CKD stage 5 were noted among those with systolic blood pressure <140 mm Hg (9.7 months longer predicted compared to actual), proteinuria <1 g/g (9.1 months), and serum albumin ≥3.5 g/dL (9.0 months). CONCLUSION: We found marked differences between the actual and predicted time spent in CKD stage 5 based on risk factors of interest. We believe that placing timing of dialysis initiation in the perspective of time is novel and may identify subgroups of patients who may derive particular benefit from a more concerted effort to delay RRT.
Authors: Srinivasan Beddhu; Matthew H Samore; Mark S Roberts; Gregory J Stoddard; Nirupama Ramkumar; Lisa M Pappas; Alfred K Cheung Journal: J Am Soc Nephrol Date: 2003-09 Impact factor: 10.121
Authors: Waqar H Kazmi; David T Gilbertson; Gregorio T Obrador; Haifeng Guo; Brian J G Pereira; Allan J Collins; Annamaria T Kausz Journal: Am J Kidney Dis Date: 2005-11 Impact factor: 8.860
Authors: Bruce A Cooper; Pauline Branley; Liliana Bulfone; John F Collins; Jonathan C Craig; Margaret B Fraenkel; Anthony Harris; David W Johnson; Joan Kesselhut; Jing Jing Li; Grant Luxton; Andrew Pilmore; David J Tiller; David C Harris; Carol A Pollock Journal: N Engl J Med Date: 2010-06-27 Impact factor: 91.245
Authors: Fan Fan Hou; Xun Zhang; Guo Hua Zhang; Di Xie; Ping Yan Chen; Wei Ru Zhang; Jian Ping Jiang; Min Liang; Guo Bao Wang; Zheng Rong Liu; Ren Wen Geng Journal: N Engl J Med Date: 2006-01-12 Impact factor: 91.245
Authors: Johanna C Korevaar; Maarten A M Jansen; Friedo W Dekker; Elisabeth W Boeschoten; Patrick M M Bossuyt; Raymond T Krediet Journal: Am J Kidney Dis Date: 2002-01 Impact factor: 8.860
Authors: Harold I Feldman; Lawrence J Appel; Glenn M Chertow; Denise Cifelli; Borut Cizman; John Daugirdas; Jeffrey C Fink; Eunice D Franklin-Becker; Alan S Go; L Lee Hamm; Jiang He; Tom Hostetter; Chi-Yuan Hsu; Kenneth Jamerson; Marshall Joffe; John W Kusek; J Richard Landis; James P Lash; Edgar R Miller; Emile R Mohler; Paul Muntner; Akinlolu O Ojo; Mahboob Rahman; Raymond R Townsend; Jackson T Wright Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2009-06-18 Impact factor: 8.237